Preliminary Program

Sessions requiring tickets are noted throughout the 2017 ASCO Annual Meeting Preliminary Program ( = Ticketed Session). Learn more about adding the Ticketed Session package to your registration.

The Preliminary Program is current as of February 08, 2017. Discover more information on the different session types at the 2017 ASCO Annual Meeting.

1:00 PM–2:15 PM

Education Sessions

Molecular Oncology Tumor Board: Double-Hit Lymphoma

Jason R. Westin, MD, MS—Chair
The University of Texas MD Anderson Cancer Center

David W. Scott, MBCHB, PhD
British Columbia Cancer Agency

Translational Scientist's Perspective


Social Media 101: A Primer for Professionals

Merry Jennifer Markham, MD—Chair 

University of Florida

Networking Through Social Media

David L. Graham, MD

Levine Cancer Institute–Cornelius-Carolinas HealthCare System

Using Social Media to Promote Patient and Community Engagement

Nikhil Wagle, MD

Dana-Farber Cancer Institute 

Using Social Media for Clinical Trials and Research Promotion


The State of the Art in High-Grade Serous Ovarian Cancer

Elise C. Kohn, MD 

National Cancer Institute at the National Institutes of Health

Update on High-Grade Serous Ovarian Carcinoma

Gordon B. Mills, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

Clinical Utility of Homologous Recombinant Deficiency as a Biomarker of Disease

S. Percy Ivy, MD

National Cancer Institute at the National Institutes of Health

Creating Synthetic Lethality


Treating Myeloma in Older Patients

Ashley Elizabeth Rosko, MD

Ohio State University Wexner Medical Center

Respecting Frailty, Fragility, or Age? How Do We Decide Treatment Intensity?

Sergio Giralt, MD 

Memorial Sloan Kettering Cancer Center 

Who Should Not Be Transplanted? Is There an Upper Age?

Maria-Victoria Mateos, MD, PhD 

University of Salamanca Hospital 

Aiming for Complete Response Irrespective of Age

Angela Dispenzieri, MD—Chair
Mayo Clinic

Myeloma in the Elderly: When Less Is More


Upfront Management of Operable Non-Small Cell Lung Cancer
Shirish M. Gadgeel, MD—Chair

Karmanos Cancer Institute

Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer

Thomas A. DiPetrillo, MD

Brown University Oncology Research Group

New Radiation Techniques in Early Non-Small Cell Lung Cancer

Hiran Chrishantha Fernando, MBBS

Boston Medical Center Surgery 

Update in Non-Small Cell Lung Cancer

Meet the Professor Session

Ticketed SessionThe Evolving Perception of Pediatric and Adult Gastrointestinal Stromal Tumor 
Jonathan C. Trent II, MD, PhD

Sylvester Comprehensive Cancer Center

Latest Advances in Adult Gastrointestinal Stromal Tumors

Lee J. Helman, MD

National Cancer Institute at the National Institutes of Health

Latest Advances in Pediatric-Type Gastrointestinal Stromal Tumors

Clinical Problems in Oncology Session

Ticketed SessionClinical Problems in the Immunotherapy, Surgery, and Radiation Therapy of Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP

Melanoma Institute Australia

Monitoring for and Management of Immune-Related Adverse Events Resulting From Checkpoint Blockade

Amit Maity, MD, PhD

University of Pennsylvania

Is There a Role for Radiation Therapy in the Management of Melanoma?

Vernon K. Sondak, MD—Chair

H. Lee Moffitt Cancer Center and Research Institute

Surgical Questions in Melanoma: Sentinel Lymph Node and Lymph Node Dissection

1:00 PM–3:15 PM

Extended Education Sessions

Biomarkers for Immunotherapy: An Illusion or a Reality?

Roy S. Herbst, MD, PhD

Yale School of Medicine

Current Status of Biomarkers for Cancer Immunotherapy

Karen L. Reckamp, MD

City of Hope Comprehensive Cancer Center

Incorporating Biomarkers Into Clinical Practice: Challenges and Opportunities

Vamsidhar Velcheti, MD—Chair

Cleveland Clinic

Biomarkers for Immune-Related Toxicities

Kurt Alex Schalper, MD, PhD

Yale University

Future Strategies for Personalized Immunotherapy

Marc S. Ernstoff, MD

Roswell Park Cancer Institute

Challenges With Identifying Patients for Combination Immunotherapy 


Constructing a Care Team for Under-resourced Populations: Reaching the Hard-to-Reach With a Multidisciplinary Approach

Michael T. Halpern, MD, PhD, MPH—Chair

College of Public Health, Temple University

Role of Advanced Practice Providers in Providing Cancer Care for Underserved Populations

Gina M. Villani, MD, MPH

The Brooklyn Hospital Center 

Incorporating Nutrition Services in Cancer Care in Low-Resource Settings

Karen Marie Winkfield, MD, PhD

Massachusetts General Hospital

Leveraging Community Social Services to Enhance Provision of Comprehensive Cancer Care

Arden M. Morris, MD, MPH

Stanford School of Medicine

Strategies to Improve Patient Engagement in Treatment Decisions at Cancer Centers and Community Oncology Practices

Manali I. Patel, MD, MPH

Stanford Hospital

Managing Insurance Issues in Providing Timely and High-Quality Cancer Care


Moving Beyond the Randomized Controlled Trial: Real-World Data to Inform Patient Care and Policy

Ronald C. Chen, MD, MPH—Chair 
The University of North Carolina at Chapel Hill

Randomized Trials As the Gold Standard With Limitations

Sean Khozin, MD, MPH

U.S. Food and Drug Administration

The FDA Perspective on Real-World Data

Alan Rosenberg, MD

Anthem, Inc.

How Does Anthem Consider Nonrandomized Data in Coverage Policies?

Lynne Penberthy, MD, MPH

National Cancer Institute at the National Institutes of Health

Deriving Research-Grade Data From Cancer Registries

Christopher Baggett, PhD

University of North Carolina at Chapel Hill

Overview of Available Real-World Data for Cancer Research

Lesley H. Curtis, PhD

Duke Clinical Research Institute

PCORnet: A Developing Data Source by Linking Electronic Medical Records


On the Shoulders of Giants: Historical Approaches to Immunotherapy in Solid Tumors

James Patrick Allison, PhD

The University of Texas MD Anderson Cancer Center

Novel Approaches to Immunotherapy in Solid Tumors

Jedd D. Wolchok, MD, PhD—Chair

Memorial Sloan Kettering Cancer Center

Novel Approaches to Immunotherapy in Solid Tumors

Sarbajit Mukherjee, MD

University of Oklahoma Health Sciences Center

Case Study Presentation and Discussion

Neil Vasan, MD, PhD

Memorial Sloan Kettering Cancer Center

Case Study Presentation and Discussion


Optimizing Endocrine Therapy and Side-Effect Mitigation Across the Disease Spectrum 

Prudence A. Francis, MD—Chair

Peter MacCallum Cancer Centre

Overview of Adjuvant Endocrine Therapy Recommendations

Ines Vaz-Luis, MD

Institut Gustave Roussy

Mitigation of Side Effects in Adjuvant Endocrine Therapy

Hope S. Rugo, MD

University of California, San Francisco

Bone Modifying Agents for Treatment and Prevention

Rachel A. Freedman, MD, MPH

Dana-Farber Cancer Institute

Adjuvant Therapy Considerations for Older Patients

Amy Sanders Clark, MD 

Hospital of the University of Pennsylvania

Evidence for and Toxicity of CDK4/6 Inhibitors

Nicholas C. Turner, MBBS, PhD

Royal Marsden NHS Foundation Trust

Do Biomarkers Help Us Select Endocrine Therapy and Combinations in Metastatic Breast Cancer?

1:00 PM–5:00 PM

Extended Education Session

Grant Writing Workshop

Mary (Nora) L. Disis, MD—Chair

University of Washington

Grant Writing Pearls

Karla V. Ballman, PhD

Weill Cornell Medicine Sandra and Edward Meyer Cancer Center

Working With a Biostatistician

Charles R. Thomas Jr., MD

Oregon Health and Science University

Choosing a Mentor and Obtaining Letters of Support

Heather L. McArthur, MD

Cedars-Sinai Medical Center

What to Do When Your First Grant Application Gets Rejected?

Dean Frohlich, PhD

Conquer Cancer Foundation of the American Society of Clinical Oncology

Conquer Cancer Foundation Grants Program

Ming Lei, PhD

National Cancer Institute at the National Institutes of Health

National Cancer Institute Training and Career Development Grants

Dawn L. Hershman, MD, MS, FASCO 

Columbia University Medical Center 

Small Group Discussion Table Leader

Kathleen A. Cooney, MD

University of Utah

Small Group Discussion Table Leader

Emile E. Voest, MD, PhD

Netherlands Cancer Institute-Antoni van Leeuwenhoek

Small Group Discussion Table Leader

Gary K. Schwartz, MD

New York-Presbyterian Hospital/Columbia University Medical Center

Small Group Discussion Table Leader

Wells A. Messersmith, MD

University of Colorado Cancer Center

Small Group Discussion Table Leader

Norah Lynn Henry, MD, PhD

University of Utah

Small Group Discussion Table Leader

2:45 PM–4:00 PM

Education Session

Operable Melanoma: Updates on Screening, Prognostication, and Adjuvant-Neoadjuvant Therapies

Sancy Ann Leachman, MD, PhD

Oregon Health and Science University

Melanoma Screening: Review of Current Evidence and Guidelines

Paul Lorigan, MD

University of Manchester

Prognostic Biomarkers in Patients with Operable Melanoma: Current Evidence

Ahmad A. Tarhini, MD, PhD—Chair 

University of Pittsburgh Cancer Institute 

Update on the Adjuvant and Neoadjuvant Therapy of High-Risk Melanoma


Meet the Professor Session

Ticketed SessionApproach to the Patient With Multiple Tumors in the Chest: Case Studies

Dennis A. Wigle, MD, PhD
Mayo Clinic


Clinical Problems in Oncology Session

Ticketed SessionNew Drugs and Therapies in Chronic Lymphoid Leukemia and Indolent Non-Hodgkin Lymphoma
Jeffrey Alan Jones, MD, MPH

The Ohio State University Comprehensive Cancer Center

Emerging Agents and Novel Combinations for Patients With Chronic Lymphoid Leukemia

Carla Casulo, MD

James P. Wilmot Cancer Institute-University of Rochester Medicine

When to Use New Agents in Follicular Lymphoma

John M. Pagel, MD, PhD—Chair

Swedish Cancer Institute

New Agent Toxicities and Understanding How to Deal With Them

2:45 PM–4:15 PM

Clinical Science Symposium

Genitourinary (Nonprostate) Cancer

3:00 PM–6:00 PM

Oral Abstract Sessions

Gynecologic Cancer

Patient and Survivor Care


3:45 PM–6:00 PM

Extended Education Sessions

Global Health Initiatives of the International Oncology Community
Peter Paul Yu, MD, FACP, FASCO—Chair

Hartford HealthCare Cancer Institute

ASCO Global Oncology Leadership Task Force Report on Global Health

Sana A. Al Sukhun, MD, MSc

The University of Jordan

Challenges of Implementing New Evidence in Limited-Resource Environments

Gilberto Lopes, MD, MBA, FAMS

University of Miami

Resource-Stratified Guidelines

Mary K. Gospodarowicz, MD

Princess Margaret Cancer Centre 

UICC Efforts to Improve Access to Radiation Therapy

Ophira M. Ginsburg, MSc, MD

Women's College Research Institute

WHO Efforts to Support Global Control of Cancer


Immunotherapy and Lung Cancer

Edward B. Garon, MD

David Geffen School of Medicine at the University of Los Angeles, California

Role of Checkpoint Inhibitors in First-Line Therapy and How to Sequence Immunotherapy

Ben C. Creelan, MD, MS

H. Lee Moffitt Cancer Center and Research Institute

What Is the Role of Immunotherapy in Patients With Mutations?

Melissa Lynne Johnson, MD—Chair

Sarah Cannon Research Institute

Are All Immunotherapy Drugs the Same or Is One the Best?

Dickran Garo Kazandjian, MD 

National Institutes of Health

Pseudoprogression: Is It Real?

Hossein Borghaei, DO, MS

Fox Chase Cancer Center

Management of Toxicity of Immunotherapy

Aaron Scott Mansfield, MD

Mayo Clinic

What Is the Role of PD-L1 Biomarker Testing in Clinical Practice?


Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence

John Ng, MD

Weill Cornell Medical College

Unresectable Pancreatic Cancer: What Is the Value Added with Radiation?

Emily K. Bergsland, MD

University of California, San Francisco

Liver-Limited Metastatic Neuroendocrine Cancer: Should We Stick With Systemic Therapy?

E. Gabriela Chiorean, MD

University of Washington 

Locally Advanced, Unresectable Pancreatic Cancer: Is Radiotherapy Necessary in 2017?

Manish A. Shah, MD—Chair

New York-Presbyterian Hospital

Implementation of Best Practice for Locally Advanced Esophageal Cancer

Prateek Sharma, MD

University of Kansas Medical Center

Management of Barrett's Esophagus and Early-Stage Esophageal Small Cell Cancer

Riad Salem, MD

Feinberg School of Medicine: Northwestern University

Interventional Radiology Approaches to Metastatic Neuroendocrine Cancers


Treatment of Relapsed Myeloma in the Era of Novel Drugs

Nina Shah, MD

The University of Texas MD Anderson Cancer Center

Are All Relapses the Same? When Do We Treat?

Laurent Garderet, MD

Hopital Saint-Antoine

Doublet Therapy Versus Triplet Therapy at Relapse: Are We Sure of the Answer?

Shaji Kumar, MD

Mayo Clinic 

Sequencing of Therapies in the Relapsed Setting

Sham Mailankody, MBBS

Memorial Sloan Kettering Cancer Center 

Can We Put a Price on Progress? Cost and Value in Myeloma Therapy

Parameswaran Hari, MD, MRCP—Chair

Medical College of Wisconsin

Transplantation After Relapse: Do We Have Cells Stored?

Saad Zafar Usmani, MD

Levine Cancer Institute–Carolinas HealthCare System

New Targets and New Drugs for Relapse

4:30 PM–6:00 PM

Education Session

Special Session for Program Directors and Key Clinical Faculty

4:45 PM–6:00 PM

Education Sessions

Improving Quality and Value of Cancer Care for Older Adults

Beverly E. Canin—Chair

Patient Advocate

Introduction and Current State of Quality and Value in Geriatric Oncology

Arash Naeim, MD, PhD

University of California, Los Angeles

Understanding Quality and Value for the Older Patient With Cancer

Andrew E. Chapman, DO

Thomas Jefferson University

Interdisciplinary Models of Care to Optimize Care Coordination Among Older Adults

Erika E. Ramsdale, MD 

University of Virginia

Implementing Geriatric Best Practices at the Point of Care


Novel Targeted Agents and Immunotherapy in Breast Cancer

Ingrid A. Mayer, MD, MSCI

Vanderbilt-Ingram Cancer Center

Future Directions in Overcoming Endocrine Resistance

Sherene Loi, MD—Chair

Peter MacCallum Cancer Centre

Novel Therapeutic Agents for HER2-Amplified Breast Cancers

Rebecca Alexandra Dent, MD

National Cancer Centre Singapore

New Approaches in Triple-Negative Breast Cancer: PARP Inhibitors and Beyond


The Value of Lymphoma and Chronic Lymphoid Leukemia Therapy: Balancing Cost and Access to Care in 2017 and Beyond 

Adrienne Alise Phillips, MD, MPH

Weill Cornell Medical College

Health Disparities and the Global Landscape of Lymphoma Care Today

Michael Pfreundschuh, MD

Universitatsklinikum des Saarlandes

Age and Gender in Non-Hodgkin Lymphoma Therapy: It Is Not All Created Equal, or Is It?

Scott David Ramsey, MD, PhD—Chair

Fred Hutchinson Cancer Research Center

Financial Impact on Patient Care for Lymphoid Diseases at the System and Global Level


Meet the Professor Session

Ticketed SessionEnhancing Community-Based Research: ASCO's Research Community Forum

Howard A. Burris III, MD

Sarah Cannon Research Institute

Effectively Bringing Research Into Clinical Practice

Nicholas J. Robert, MD

The US Oncology Network

Effectively Bringing Research Into Clinical Practice


Clinical Problems in Oncology Session

Ticketed SessionHow to Integrate Multimodal Therapy Into the Management of Castration-Resistant Prostate Cancer

Phuoc T. Tran, MD, PhD 

Johns Hopkins University School of Medicine

Stereotactic Body Radiation: What Is Its Role in Advanced Disease?

Ana Aparicio, MD—Chair

The University of Texas MD Anderson Cancer Center

Chemotherapy for Metastatic Castration-Resistant Prostate Cancer: Which Patient? Which Time?

Johann S. De Bono, MD, MSc, PhD, FRCP, FMedSci, MBChB

The Institute of Cancer Research, London 

Targeting DNA Repair Mutations in Metastatic Castration-Resistant Prostate Cancer